Ventyx Biosciences Inc. Common Stock VTYX · Stock Open Ventyx Biosciences Inc. Common Stock in new tab
Ventyx Biosciences Inc. Common Stock Analysis (VTYX)
Is Ventyx Biosciences Inc. Common Stock a good investment? Ventyx Biosciences Inc. Common Stock (VTYX) is currently trading at 14.00 USD. Market analysts have a consensus price target of 13.00 USD. This suggests the asset is currently trading above analyst expectations.
Investor FAQ
Does Ventyx Biosciences Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Ventyx Biosciences Inc. Common Stock?
Ventyx Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in a Phase 2a trial for patients with early Parkinson's disease and is in a Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California. As of March 4, 2026, Ventyx Biosciences, Inc. operates as a subsidiary of Eli Lilly and Company.
Community Discussion